Back to today’s briefing

Story perspectives

New Drug Cuts Alzheimer’s Risk by 50% in Trials

3/21/2025

40 9

Summary

Story summary

A groundbreaking clinical trial from Washington University reveals that the anti-amyloid drug gantenerumab can cut the risk of Alzheimer’s symptoms by 50% in those genetically at risk. Published in The Lancet Neurology, these findings illuminate a promising path to delaying cognitive decline by tackling amyloid plaques before they trigger symptoms, igniting hope for Alzheimer’s prevention.

1 of 1

Story summary

A groundbreaking clinical trial from Washington University reveals that the anti-amyloid drug gantenerumab can cut the risk of Alzheimer’s symptoms by 50% in those genetically at risk. Published in The Lancet Neurology, these findings illuminate a promising path to delaying cognitive decline by tackling amyloid plaques before they trigger symptoms, igniting hope for Alzheimer’s prevention.